Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

This case study reports on an adult with metastatic Crohn's disease treated with infliximab over 4.5 years, providing valuable follow-up data in this context.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Upadacitinib effectively treats pyoderma gangrenosum.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.

In this case report, a 31-year-old male with refractory sycosis barbae achieved complete remission after 4 months of treatment with bimekizumab, suggesting this dual inhibitor of interleukin-17A and IL-17F may be a promising therapy for this condition.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This case report describes a patient with Crohn's disease developing alopecia and psoriasiform skin lesions while on adalimumab treatment.

This study found that long-term imiquimod treatment on mice intensified skin inflammation early on, but topical corticosteroids significantly reduced skin infiltration and inflammatory cytokines after initial inflammation subsided.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

In this study, researchers reported a 1.33% prevalence of scarring alopecia among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, noting that hair loss did not require treatment discontinuation and seemed to coincide with favorable cancer outcomes.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.

In this case report, a 7-year-old girl with severe alopecia areata and high baseline IgE levels achieved complete hair regrowth after 48 weeks of dupilumab therapy, with observed decreases in IgE levels and no significant adverse effects beyond a mild initial allergic reaction.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This report describes two patients with atopic dermatitis receiving dupilumab, where one experienced healing of alopecia areata and the other developed it, illustrating the drug's varied effects.